In the realm of predictive drugs for RA treatment, focusing on DE-CRGs, our analysis pinpointed several key targets, notably ATP7A, ATP7B, SLC31A1, GLS, and NFE2L2. Here, NFE2L2 is linked to rheumatoid arthritis.